Sol-Gel Technologies Ltd. Reports Third Quarter 2026 Financial Results and SGT-610 Clinical Progress

Sol-Gel Technologies Ltd. announced its financial results for the third quarter ended September 30, 2026, and provided c...

By Dhallo News · November 13, 2026 at 1:51 PM IST

Sol-Gel Technologies Ltd. announced its financial results for the third quarter ended September 30, 2026, and provided corporate updates. The company reported that its pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for the prevention of basal cell carcinoma lesions

SOURCE: Nasdaq

ORIGINAL REPORT: Click here

DHALLO EDITORIAL STATUS: Aggregated & reviewed

Have feedback on this article?Report error or suggestion

Sol-Gel Technologies Ltd. Reports Third Quarter 2026 Financial Results and SGT-610 Clinical Progress

Read More from Markets

ICTSI: Keen to Expand in Southern, Western Africa

Odd Lots: Why a $2 Billion Law Firm Suddenly Collapsed (Podcast)

23% return in 3 months: PL Capital sees 12.6% upside potential in Welspun Enterprises - Check target price, rationale

5 minutes. The news that matters.